Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Esomeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 7/20 | 0.50 |
| ▸ | ATP4B known ✓ | P51164 | 7/20 | 0.50 |
| ▸ | BRS3 | P32247 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.50 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.50 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.50 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.50 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.50 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.50 |
| ▸ | FXYD2 | P54710 | 4/20 | 0.50 |
| ▸ | ATP1A4 | Q13733 | 4/20 | 0.50 |
| ▸ | WDR5 | P61964 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.50 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omeprazole SCHEMBL28256110 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL30179968 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL1560978 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL29538900 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL1560726 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL1191 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL82985 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL29350786 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL29673044 | 1.00 | BRS3 (0.52) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL23780638 | 0.99 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18313 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| CN-122056845-A | Esomeprazole enteric capsule, and preparation method and application thereof | 通化万通药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4735895-A1 | HELICOBACTER CAGA PEPTIDES AND THEIR USE IN DIAGNOSIS | Biotome Pty Ltd (AU) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731180-A1 | A POWDER COMPOSITION FOR ORAL SUSPENSION OF PROTON PUMP INHIBITORS AND THE METHOD OF PREPARING THE SAME | Orbit Pharma Limited (GB) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260108504-A1 | ENTERIC COATED TABLET WITH ACECLOFENAC AND PARACETAMOL TABLET AND PROCESS OF PREPARATION THEREOF | ATOZ PHARMACEUTICALS PVT LTD (IN) | 2026-04-23 | — | — | US | claimed |
| US-20260097026-A1 | INHIBITION OF AORTIC VALVE CALCIFICATION | ZABIRNYK ARSENII (NO) | 2026-04-09 | — | — | US | claimed |
| WO-2000072838-A1 | NEW USE OF COMPOUNDS AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2000-12-07 | — | — | WO | claimed |
| EP-1037607-A1 | NOVEL SUPPOSITORY FORM COMPRISING AN ACID-LABILE ACTIVE COMPOUND | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2000-09-27 | — | — | EP | claimed |
| WO-2000050037-A1 | NITROSATED AND NITROSYLATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-08-31 | — | — | WO | claimed |
| WO-2000044744-A1 | POTASSIUM SALT OF ($I(S))-OMEPRAZOLE | ASTRAZENECA AB (SE) | 2000-08-03 | — | — | WO | claimed |
| WO-2000030612-A1 | A METHOD OF PRODUCING DRUG PARTICLES | ASTRAZENECA AB (SE) | 2000-06-02 | — | — | WO | claimed |
| WO-2000028975-A2 | IMPROVED CHEMICAL PROCESS AND PHARMACEUTICAL FORMULATION | ASTRAZENECA AB (SE) | 2000-05-25 | — | — | WO | claimed |
| WO-2000009092-A1 | ORAL ADMINISTRATION FORM FOR PYRIDIN-2-YLMETHYLSULFINYL-1H-BENZIMIDAZOLES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-02-24 | — | — | WO | claimed |
| WO-1999063940-A2 | INHIBITORS OF H+K+-ATPase | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1999029299-A1 | NOVEL SUPPOSITORY FORM COMPRISING AN ACID-LABILE ACTIVE COMPOUND | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-06-17 | — | — | WO | claimed |
| EP-0101136-A2 | Catalyst for polymerizing olefins, component thereof and process of producing said component | STAUFFER CHEMICAL COMPANY (US) | 1984-02-22 | — | — | EP | claimed |